tbuckley/cabot-search huggingface dataset:
Caspase-1 Cleavage of the TLR Adaptor TRIF Inhibits Autophagy and β-Interferon Production during Pseudomonas aeruginosa Infection
Authors: Majid Sakhi Jabir, Neil D. Ritchie, Dong Li, Hannah K. Bayes, Panagiotis Tourlomousis, Daniel Puleston, Alison Lupton, Lee Hopkins, Anna Katharina Simon, Clare Bryant, Thomas J. Evans
Journal: Cell Host & Microbe (2014)
Mitral valve reconstruction by posterior cusp advancement using a pericardial graft. Long-term follow-up in nine patients.
Authors: J K Ross, E G Olsen
Journal: Thorax (1976)

Between December 1964 and March 1969, 11 posterior cusp advancement operations were carried out for patients with mitral valve disease in whom there was posterior cusp deficiency. Seven of the nine long-term survivors have required reoperation for recurrent mitral regurgitation, combined in six instances with stenosis of varying severity, the interval between the first and second operations ranging from five months to nine years (average 57-5 months). Histological examination of the pericardial grafts recovered at re-operation has been made and shows that after an initial period during which the graft retains near normal structure, there is a progressive degeneration with fibrous tissue replacement. This process takes place on both surfaces of the graft where there is evidence of vascularization in the zone between the graft remnant and the overlying and increasingly thick fibrous tissue covering. The conclusion drawn from the experience with this small series is that the long-term performance of pericardial grafts designed to restore function to the posterior cusp of the mitral valve is poor and unpredictable.
Intrathecal Gene Therapy Corrects CNS Pathology in a Feline Model of Mucopolysaccharidosis I
Authors: Christian Hinderer, Peter Bell, Brittney L Gurda, Qiang Wang, Jean-Pierre Louboutin, Yanqing Zhu, Jessica Bagel, Patricia O'Donnell, Tracey Sikora, Therese Ruane, Ping Wang, Mark E Haskins, James M Wilson
Journal: Molecular Therapy (2014)

Enzyme replacement therapy has revolutionized the treatment of the somatic manifestations of lysosomal storage diseases (LSD), although it has been ineffective in treating central nervous system (CNS) manifestations of these disorders. The development of neurotrophic vectors based on novel serotypes of adeno-associated viruses (AAV) such as AAV9 provides a potential platform for stable and efficient delivery of enzymes to the CNS. We evaluated the safety and efficacy of intrathecal delivery of AAV9 expressing α-l-iduronidase (IDUA) in a previously described feline model of mucopolysaccharidosis I (MPS I). A neurological phenotype has not been defined in these animals, so our analysis focused on the biochemical and histological CNS abnormalities characteristic of MPS I. Five MPS I cats were dosed with AAV9 vector at 4–7 months of age and followed for 6 months. Treated animals demonstrated virtually complete correction of biochemical and histological manifestations of the disease throughout the CNS. There was a range of antibody responses against IDUA in this cohort which reduced detectable enzyme without substantially reducing efficacy; there was no evidence of toxicity. This first demonstration of the efficacy of intrathecal gene therapy in a large animal model of a LSD should pave the way for translation into the clinic. Enzyme replacement therapy has revolutionized the treatment of the somatic manifestations of lysosomal storage diseases (LSD), although it has been ineffective in treating central nervous system (CNS) manifestations of these disorders. The development of neurotrophic vectors based on novel serotypes of adeno-associated viruses (AAV) such as AAV9 provides a potential platform for stable and efficient delivery of enzymes to the CNS. We evaluated the safety and efficacy of intrathecal delivery of AAV9 expressing α-l-iduronidase (IDUA) in a previously described feline model of mucopolysaccharidosis I (MPS I). A neurological phenotype has not been defined in these animals, so our analysis focused on the biochemical and histological CNS abnormalities characteristic of MPS I. Five MPS I cats were dosed with AAV9 vector at 4–7 months of age and followed for 6 months. Treated animals demonstrated virtually complete correction of biochemical and histological manifestations of the disease throughout the CNS. There was a range of antibody responses against IDUA in this cohort which reduced detectable enzyme without substantially reducing efficacy; there was no evidence of toxicity. This first demonstration of the efficacy of intrathecal gene therapy in a large animal model of a LSD should pave the way for translation into the clinic.
ACOG Renews Domestic Violence Campaign, Calls for Changes in Medical School Curricula
Authors: Ten Randall
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE GROWTH OF CHICKEN BONE MARROW IN VITRO AND ITS BEARING ON HEMATOGENESIS IN ADULT LIFE
Authors: Nathan Chandler Foot
Journal: The Journal of Experimental Medicine (1913)

1. The development of the polymorphonuclear leucocyte from a mesenchymal, lymphoid type of cell is possible in adult life and in vitro in chicken bone marrow. 2. These cells can rapidly proliferate by means of amitotic division of an unripe form very similar to, but smaller than themselves. 3. All the cells of chicken bone marrow can undergo a transformation to a type of cell resembling, although not proved to be identical with the cells of connective tissue.
SPLENOMEGALY WITH PROGRESSIVE ASCITES AND LOUD VENOUS HUM: Spontaneous Cure of Ascites by Leakage through Abdominal Walls
Authors: A. J. Hall
Journal: BMJ (1922)

Tm BBrJou I 1sZDICAL JrON3XZWhere the' position of the appendix is known before operation to be abniormal, a in Case 49, a suitable incision is used.Only one case of hernia has been recorded as a sequence of the operation.The following table shows why operation was under- taken and the result: Total.Recoveries.Deaths.; Mortality.Per cent.Acute appendicitis without 22 22 0 0 peritonitis Acute appendicitis with-pelvic 29 27 2 6.8 peritonitis Acut9-4ppendicitis with 5 4 1 20 general peritonitis Actite apmpendicitis with loca- it 14 O O lized
Interferon-α Treatment and Formation of Factor VIII Antibodies
Authors: Raphael B. Stricker
Journal: Annals of Internal Medicine (1997)

Letters15 May 1997Interferon-α Treatment and Formation of Factor VIII AntibodiesRaphael B. Stricker, MDRaphael B. Stricker, MDCalifornia Pacific Medical Center, San Francisco, CA 94120Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-126-10-199705150-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Mauser-Bunschoten and colleagues [1] describe an apparent lack of association between formation of factor VIII inhibitors and long-term interferon-α therapy in patients with hemophilia A and chronic hepatitis C. The study addresses two reports of acquired factor VIII inhibitors in “dissimilar” patients with and without hemophilia who received long-term interferon-α treatment [2, 3]. Although the current findings are reassuring, they also raise intriguing questions about the pathogenesis of factor VIII antibodies and interferon-α-induced autoimmunity.Factor VIII inhibitors may arise as alloantibodies in patients with severe hemophilia A (factor VIII level < 1%) or as autoantibodies in persons ...References1. Mauser-Bunschoten EP, Damen M, Reesink HW, Roosendaal G, Chamuleau RA, van den Berg HM. Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C. Ann Intern Med. 1996; 125:297-9. Google Scholar2. Stricker RB, Barlogie B, Kiprov DD. Acquired factor VIII inhibitor associated with chronic interferon-α therapy. J Rheumatol. 1994; 21:350-2. Google Scholar3. Castenskiold EC, Colvin BT, Kelsey SM. Acquired factor VIII inhibitor associated with chronic interferon-α therapy in a patient with haemophilia A. Br J Haematol. 1994; 87:434-6. Google Scholar4. Green D. Immunosuppression of factor VIII inhibitors in nonhemophilic patients. Semin Hematol. 1993; 30:28-31. Google Scholar5. Ariad S, Song E, Cohen R, Bezwoda WR. Interferon-α induced autoimmune hepatitis in a patient with Philadelphia chromosome-positive chronic myeloid leukemia with cytogenetically normal T lymphocytes. Mol Biother. 1992; 4:139-42. Google Scholar Author, Article, and Disclosure InformationAuthors: Raphael B. Stricker, MDAffiliations: California Pacific Medical Center, San Francisco, CA 94120 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 May 1997Volume 126, Issue 10Page: 829KeywordsAntibodiesAutoantibodiesAutoimmunityChronic hepatitis CHemophiliaHemophilia AHemorrhageImmunosuppressivesPathogenesis ePublished: 15 August 2000 Issue Published: 15 May 1997 Copyright & PermissionsCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Abstract PD5-3: Anti-metastatic activity, chemotherapeutic enhancement and therapeutic potential of targeting Hsp90 with ganetespib in triple negative breast cancer
Authors: DA Proia, C Zhang, M Sequeira, J-P Jimenez, S He, M Nagai, JL Acquaviva, DL Smith, J Sang, I El-Hariry
Journal: Cancer Research (2013)

Abstract Background: While the incidence of triple negative breast cancer (TNBC) is only 10-20%, these tumors show a disproportionate mortality for breast cancer patients. Due to a lack of effective molecular targets in this disease, therapeutic options are largely limited to systemic chemotherapeutic approaches which have shown disappointing efficacy in the metastatic setting. Here we undertook a comprehensive evaluation of the activity of the drug candidate, ganetespib, a potent inhibitor of heat shock protein 90 (Hsp90), in this malignancy. Methods: The sensitivity of TNBC cells to ganetespib was determined in viability assays using a panel of tumor lines. The effects of ganetespib exposure on client proteins and their effector pathways were examined by Western blot and reverse phase protein array analysis. The anti-metastatic activity of ganetespib was evaluated using a 4T1 metastasis model. Combinatorial drug analyses were performed with chemotherapeutic agents. DNA damage and cell cycle disruption were assessed using the comet assay, Western blotting and fluorescence microscopy. The in vivo efficacy of the compound, both as a single agent and in combination, was established using MDA-MB-231 xenograft models. Computed tomography scans were obtained for a metastatic TNBC patient undergoing ganetespib treatment. Results: Ganetespib reduced cell viability in TNBC cell lines with low nanomolar potency. Ganetespib treatment induced robust destabilization of multiple client proteins and oncogenic signaling pathways and suppressed lung metastasis in the experimental model. Ganetespib potentiated the cytotoxic activity of doxorubicin via enhanced DNA damage and mitotic arrest, conferring superior efficacy to the doxorubicin + cyclophosphamide (AC) regimen in MDA-MB-231 xenograft models. Ganetespib also promoted mitotic catastrophe and apoptosis in combination with taxanes in vitro, and these effects translated to significantly improved combinatorial activity in vivo. Marked tumor shrinkage of metastatic lung lesions was seen in the patient while on ganetespib monotherapy. Conclusion: The preclinical activity profile and clinical evidence of tumor regression suggest that ganetespib offers considerable promise as a new therapeutic candidate to target TNBC. In particular, the capacity of ganetespib to potentiate the activity of standard of care chemotherapeutics provides a rationale for the exploration of this agent in novel combinatorial treatment strategies for this disease. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr PD5-3.
Crash Call — None for the Road — Medical Defense
Authors: John Lister
Journal: New England Journal of Medicine (1967)

AS cardiac monitors, pacemakers and defibrillators become standard equipment in hospitals, the routine of the "crash call" must become accepted as part of the discipline for a resident medical staff.When a case of cardiac or respiratory arrest occurs, the alarm is raised, and a chain of events set in motion that should lead to the speedy arrival of a resuscitation team and its equipment in whatever ward or department of the hospital the patient may be. Speed being the operative word, no time must be lost in questioning the call, and on arrival at the scene, immediate resuscitation measures . . .
Screening for Colorectal Cancer: Which Test Is Best?
Authors: Lawrence M. Pickover
Journal: JAMA (1994)

To the Editor.  —The article by Drs Lang and Ransohoff 1 does not take issue with the evidence that FOBT screening reduces mortality. The authors feel that the reduction in mortality may be attributable to chance selection for colonoscopy. They conclude their article stating that annual FOBT with rehydration of slides should not be advocated at the present time. I would think that one could reach the opposite conclusion from their data and conclude that rehydration should be done with enthusiasm. How else am I to bring a patient to a potentially lifesaving colonoscopy?  If a hypothetical patient sees me, appears to be in the colon cancer age group, and is highly motivated to prevent colon cancer, it does not seem acceptable to simply schedule him or her for a colonoscopy. There are no published guidelines that would support one in that action. In fact, in the recommendations of the
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas
Authors: Pankaj Gupta, David M. Goldenberg, Edmund A. Rossi, Thomas M. Cardillo, John C. Byrd, Natarajan Muthusamy, Richard R. Furman, Chien-Hsing Chang
Journal: Blood (2012)
Breast Cancer
Authors: Cindy B. Matsen, Leigh A. Neumayer
Journal: JAMA Surgery (2013)

Breast cancer care is complex and requires a multidisciplinary approach. In this study, we provide an overview of current practices for the diagnosis and treatment of breast cancer for surgical practitioners who do not focus on this disease. We include studies published in high-impact, peer-reviewed journals that have informed or altered the standard of care, with preference given to large, multicenter, randomized clinical trials when available. Our study highlights that the surgical management of breast cancer has changed dramatically over the past decades. As our understanding of the disease process increases, practice guidelines will continue to evolve.
Characteristics of a cell line (tong/HCC) established from a human hepatocellular carcinoma
Authors: Douglas Stevenson, Jiing-Huey Lin, Myron J. Tong, June G. Marshall
Journal: Hepatology (1987)

A continuous adherent cell line was established from a hepatocellular carcinoma of an HBsAg-positive Italian male. This cell line, designated Tong/HCC, has been grown in a hormone-supplemented medium for more than 18 months. The cell line secretes HBsAg, α-fetoprotein, albumin and α 1 -antitrypsin. α-Fetoprotein production is enhanced by the addition of hydrocortisone and appears to be glucocorticoid concentration-dependent. The concentrates of the supernatant from the cell cultures and cell lysates were negative when tested for HBeAg. The cell culture medium was negative for hepatitis B virus DNA when tested by dot-blot hybridization. However, hepatitis B virus DNA was found to be integrated in the chromosomal DNA by Southern blot analysis. At least five different integration sites were identified, and no free hepatitis B virus DNA was observed. The modal chromosome number was 64, and a translocation on Chromosome 15 was consistently noted. HLA typing revealed sites for A3, Aw24, Bw34 and Cw1.
Factor V Leiden: should we screen oral contraceptive users and pregnant women?
Authors: J. P Vandenbroucke, F. J M van der Meer, F. M Helmerhorst, F. R Rosendaal
Journal: BMJ (1996)

The factor V Leiden mutation is the most common genetic risk factor for deep vein thrombosis: it is present in about 5% of the white population.The risk of deep vein thrombosis among women who use oral contraceptives is greatly increased by the presence of the mutation.The same seems to be true of the risk ofpostpartum thrombosis.Several authors have called for all women to be screened before prescription of oral contraceptives and during pregnancy.Such a policy might deny effec- tive contraception to a substantial number of women while preventing only a small number of deaths due to pulmonary emboli.Moreover, in pregnancy the ensuing use of oral anticoagulation prophylaxis might carry a penalty offatal bleeding that is equal to or exceeds the risk of death due to postpartum thrombosis.It might pay, however, to take a personal and family history of deep vein thrombosis when prescribing oral contraceptives or at a first antenatal visit to detect women from families with a tendency to multiple thrombosis.
LENGTH OF HOSPITAL STAY AND ASSOCIATED CLINICAL OUTCOMES IN ELDERLY PATIENTS FOLLOWING PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: A REPORT FROM THE NCDR®
Authors: Rajesh V. Swaminathan, Sunil V. Rao, Lisa A. McCoy, Luke K. Kim, Robert M. Minutello, S. Chiu Wong, David C. Yang, Paramita Saha-Chaudhuri, Harsimran Singh, Geoffrey Bergman, Dmitriy N. Feldman
Journal: Journal of the American College of Cardiology (2014)
Abstract B13: FGFR2 as a therapeutic target in squamous cell lung carcinoma
Authors: Rachel G. Liao, Peter Hammerman, Andrey Sivachencko, Heidi Greulich, Gad Getz, Qingsong Liu, Nathanael Gray, Matthew Meyerson
Journal: Clinical Cancer Research (2012)

Abstract Squamous cell lung carcinoma (lung SCC)) is the second most common subtype of non-small cell lung cancer, with 40,000 new cases diagnosed every year in the United States. Unlike lung adenocarcinoma, few targetable genomic events are known drivers of lung SCC, and therefore, therapeutic options are limited for patients with this disease. As part of The Cancer Genome Atlas (TCGA) project, we have analyzed the entire coding sequence of 196 lung SCCs for mutated genes which may be amenable to targeted therapeutics. In the 196 patient samples analyzed to date, we have observed mutations in the Fibroblast Growth Factor Receptor 2 (FGFR2) kinase gene in ten cases, or 5% of samples. The observed FGFR2 mutations are present in both the extracellular domain and the kinase domain of the protein, an observation that is consistent with activating mutations in FGFR2 that are known to drive endometrial cancer. We therefore hypothesized that these mutations are oncogenic and may be driving transformation in a subset of lung SCC patients. Expression of mutated FGFR2 in NIH-3T3 cells led to anchorage-independent colony formation, which was inhibited by treatment with the pan-FGFR inhibitor FIIN-1. A known mechanism of FGFR2 activation is the constitutive dimerization of receptors with mutated extracellular domains via intermolecular disulfide bond formation, and we have observed this phenomenon in two of our ECD mutants as well. These data suggest that both ECD and kinase mutations in the FGFR2 gene are sufficient to transform cells. This finding, along with recently published data suggesting that FGFR1 amplification is also able to drive lung SCC development, demonstrates that the FGFR family may be a promising therapeutic target in lung SCC.
Endoscopic Treatment of Gallstone-Impacted Choledochocele Precisely Diagnosed by Endoscopic Ultrasonography
Authors: S. Tanno, H. Maguchi, T. Obara, T. Fujii, S. B. Santos, A. Itoh, N. Nishino, S. Arisato, H. Ura, Y. Kohgo
Journal: Endoscopy (1996)
Effect of Parenterally Administered Gold Therapy on the Course of Adult Rheumatoid Arthritis
Authors: Wallace V. Epstein, Curtis J. Henke, Edward H. Yelin, Patricia P. Katz
Journal: Annals of Internal Medicine (1991)

Objective: To describe the course of rheumatoid arthritis over 5 years in adults and to evaluate the effect of parenterally administered gold salts on that course. Design: A prospective observational study of adults with rheumatoid arthritis. Data derived from annual interviews with patients from 1983 to 1988 and from physician surveys in 1983 and 1987. Setting: Rheumatology practices in the community. Patients: The study began in 1982 with 822 adults who had rheumatoid arthritis and were under the care of rheumatologists. Interventions: Those selected by rheumatologists in the management of their patients. Measurements: Information describing sociodemographic and clinical characteristics, course, and therapy was collected from patients and verified by physician reports. Functional status, measured by the Health Assessment Questionnaire, and the number of painful joints were used as outcome variables. Outcome variables were adjusted for age, sex, disease duration, baseline values of the outcome variable, and the use of four disease-remittive agents other than gold. Main Results: Multivariate repeated-measures analysis of variance showed no change in the course of rheumatoid arthritis over 5 years. The use of parenteral gold for at least 2 consecutive years at the start of the observation period produced, on average, no change in the course over 5 years in the two outcome variables. Conclusion: In our study of a community-based population of adults with rheumatoid arthritis who were under the care of community rheumatologists, we found that there was, on average, no statistically significant change in function or number of painful joints between 1983 and 1988. Patients receiving parenteral gold therapy for at least 2 consecutive years did not show a statistically significant difference in outcome when compared with those not receiving such therapy.
THE TIME ELEMENT IN GALLSTONE FORMATION
Authors: ANGUS L. CAMERON
Journal: JAMA (1923)

Although it is well known that small concretions can be produced experimentally in the gallbladder of laboratory animals within a period of a few days—ten days according to Klivert1—and that small deposits of bile elements may occur around suture material within a few weeks after its insertion into the human gallbladder, yet conclusive proof concerning the rapidity with which well developed calculi may form in the human gallbladder is lacking. Rolleston2quotes Mignot3to the effect that it takes five or six months to form a stratified, well-formed biliary calculus. Moynihan4cites a case reported by Rokitzski5of a probably rapid formation of gallstones in a typhoid fever patient, aged 26, who was operated on at the end of the third week of her illness because of a suppurative cholecystitis. Fiftyeight apparently recently formed cholesterin calculi, showing a radiate arrangement, were removed. Cultures of